Search Results for "Abilify Maintena"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Abilify Maintena. Results 1 to 3 of 3 total matches.
See also: aripiprazole
In Brief: Three New Injectable Antipsychotic Drugs
The Medical Letter on Drugs and Therapeutics • Dec 25, 2023 (Issue 1692)
Aripiprazole –
Abilify Maintena (Otsuka/Lundbeck) 300, 400 mg prefilled syringes, vials 400 mg IM once/month4 ...
Three extended-release injectable formulations of
second-generation antipsychotic drugs — two of
risperidone (Rykindo, Uzedy) and one of aripiprazole
(Abilify Asimtufii) — have been approved by the FDA
for treatment of schizophrenia in adults. Rykindo and
Abilify Asimtufii are also approved for maintenance
treatment of bipolar I disorder in adults. Other
extended-release injectable formulations of
risperidone and aripiprazole have been available in
the US for years (see Table 1).
Med Lett Drugs Ther. 2023 Dec 25;65(1692):207-8 doi:10.58347/tml.2023.1692d | Show Introduction Hide Introduction
Drugs for Bipolar Disorder
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024 (Issue 1699)
Antipsychotics
Aripiprazole4 – Abilify Maintena 300, 400 mg prefilled syringes, vials 400 mg IM once/month17 400 ...
Bipolar disorder is characterized by episodes of
mania, hypomania, and depression. Recurrences of
manic or (more frequently) depressive symptoms
are common. About 15-20% of patients with bipolar
disorder die by suicide.
Med Lett Drugs Ther. 2024 Apr 1;66(1699):49-54 doi:10.58347/tml.2024.1699a | Show Introduction Hide Introduction
In Brief: Twice-Yearly Paliperidone (Invega Hafyera) for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Jan 10, 2022 (Issue 1641)
– Abilify Maintena 300, 400 mg prefilled syringes, vials 400 mg IM once/month $2388.50
(Otsuka/Lundbeck ...
Invega Hafyera (Janssen), a long-acting, extended-release
(ER) formulation of the second-generation
antipsychotic paliperidone palmitate, has been
approved by the FDA for twice-yearly IM treatment
of schizophrenia in adults who have been adequately
treated with another injectable ER formulation of the
drug (Invega Sustenna or Invega Trinza). It is the first
drug to become available in the US for twice-yearly
treatment of schizophrenia.